Email updates

Keep up to date with the latest news and content from BMC Neuroscience and BioMed Central.

Open Access Highly Accessed Research article

Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA

Virginia B Mattis1, Marina Y Fosso2, Cheng-Wei Chang2 and Christian L Lorson1*

Author Affiliations

1 Department of Veterinary Pathobiology, Bond Life Sciences Center, University of Missouri, Columbia MO, USA

2 Department of Chemistry and Biochemistry, Utah State University, Logan UT, USA

For all author emails, please log on.

BMC Neuroscience 2009, 10:142  doi:10.1186/1471-2202-10-142

Published: 30 November 2009

Abstract

Background

Spinal Muscular Atrophy (SMA) is the leading genetic cause of infantile death. It is caused by the loss of functional Survival Motor Neuron 1 (SMN1). There is a nearly identical copy gene, SMN2, but it is unable to rescue from disease due to an alternative splicing event that excises a necessary exon (exon 7) from the majority of SMN2-derived transcripts. While SMNΔ7 protein has severely reduced functionality, the exon 7 sequences may not be specifically required for all activities. Therefore, aminoglycoside antibiotics previously shown to suppress stop codon recognition and promote translation read-through have been examined to increase the length of the SMNΔ7 C-terminus.

Results

Here we demonstrate that subcutaneous-administration of a read-through inducing compound (TC007) to an intermediate SMA model (Smn-/-; SMN2+/+; SMNΔ7) had beneficial effects on muscle fiber size and gross motor function.

Conclusion

Delivery of the read-through inducing compound TC007 reduces the disease-associated phenotype in SMA mice, however, does not significantly extend survival.